Investing.com - Financial Markets Worldwide

Aslan Fred, Artiva Biotherapeutics president, sells $69,579 in shares

Published 19/08/2025, 01:48
Aslan Fred, Artiva Biotherapeutics president, sells $69,579 in shares
ARTV
-3.36%

Artiva Biotherapeutics Inc . (NASDAQ:ARTV) President and CEO Aslan Fred, has sold 25,500 shares of common stock on August 15, 2025, according to a new SEC filing. The shares were sold at a price of $2.7286, for a total value of $69,579. The price range for the shares sold was between $2.60 and $2.80. The transaction comes as the stock has shown strong momentum, posting a 25.5% gain over the past week, according to InvestingPro data.

The filing also indicates the disposition of 4,472 shares of common stock on May 15, 2025, and another 4,472 on August 15, 2025, to cover tax obligations, with the total value of these transactions being $21,823 and price range between $2.13 and $2.75. Despite recent insider sales, analysts maintain a strong buy consensus with price targets ranging from $10 to $19, as revealed by InvestingPro analysis.

Following these transactions, Aslan Fred directly owns 382,221 shares of Artiva Biotherapeutics. The company, currently valued at $67 million, maintains strong liquidity with a current ratio of 13.8, though InvestingPro data indicates it’s burning through cash rapidly. For comprehensive insider trading analysis and 12 additional ProTips, explore the full InvestingPro Research Report.

In other recent news, H.C. Wainwright has assumed coverage on Artiva Biotherapeutics with a Buy rating. The firm set a price target of $12.00, indicating confidence in the company’s prospects. Analysts at H.C. Wainwright see potential in Artiva’s primary asset, AB-101, particularly for its application in treating autoimmune diseases. They emphasize the possible effectiveness of AB-101 when combined with anti-CD20 monoclonal antibodies. This development highlights the company’s focus on advancing allogeneic NK cell therapy. These recent developments reflect the firm’s positive outlook on Artiva’s future in the biotherapeutics field. Investors may find this update noteworthy as it underscores the potential of Artiva’s innovative therapies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.